D3 bio is a global biotechnology company focusing on the development of cancer and immune precision therapy drugs
Location: China
Employees: 11-50
Total raised: $348M
Founded date: 2020
Investors 1
| Date | Name | Website |
| 09.02.2022 | Matrix Par... | matrixpart... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 14.12.2025 | Series B | $108M | Temasek Ho... |
| 08.04.2024 | - | $40M | - |
| 18.11.2020 | Series A | $200M | - |
Mentions in press and media 17
| Date | Title | Description |
| 20.03.2026 | D3 Bio to Showcase Its Innovative KRAS Pipeline at AACR 2026, Including an Oral Presentation at Clinical Plenary Session | SHANGHAI, March 20, 2026 /PRNewswire/ -- D3 Bio Inc, a global clinical-stage biotechnology company focused on developing transformative oncology therapeutics, is pleased to announce that five abstracts have been accepted for presentation at... |
| 19.01.2026 | D3 Bio Receives U.S. FDA Clearance for Two IND Applications, Enabling Phase 1 Trial of D3S‑003 and Phase 2 Combination Study of Elisrasib (D3S‑001) with D3S‑002 | SHANGHAI, Jan. 19, 2026 /PRNewswire/ -- D3 Bio, a global clinical‑stage biotechnology company focused on developing transformative oncology therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has cleared two Inves... |
| 15.12.2025 | D3 Bio Secures $108M to Advance Cancer Drug Trials Globally | D3 Bio, a Shanghai-based biotech, just raised $108 million. This Series B funding fuels late-stage trials. The focus? Elisrasib, a drug targeting KRAS G12C-mutant cancers. Trials will span the US, China, and Europe. The company aims for glo... |
| 14.12.2025 | D3 Bio: $108 Million Series B Raised To Fund Global Phase III Trials For Lead KRAS G12C Program | D3 Bio has raised $108 million in a Series B financing round to support late-stage clinical development of its lead oncology candidate and advance a broader pipeline of targeted and immuno-oncology programs. The Shanghai-based clinical-stag... |
| 12.12.2025 | Temasek-backed D3 Bio secures $108 M Series B funding to advance global clinical programs | A $108 million Series B financing round has been completed, according to D3 Bio, a global clinical-stage biotechnology company dedicated to the discovery and development of novel oncology therapeutics. A notable group of investors, includin... |
| 11.12.2025 | Temasek, HongShan-backed D3 Bio raises $108m in Series B round | - |
| 10.12.2025 | D3 Bio Secures $108M in Series B Funding | D3 Bio, a Shanghai, China-based clinical-stage biotechnology company, raised $108M in Series B funding. The round was led by IDG Capital and SongQing Capital. Existing investors WuXi AppTec’s Corporate Venture Fund, Temasek, HSG, MPCi, and ... |
| 10.12.2025 | Chinese biotech led by AstraZeneca veteran reels in $108M for KRAS phase 3 plans | A Chinese biotech helmed by an AstraZeneca veteran has secured $108 million in series B funds, which the company will use to advance its lead KRAS inhibitor into phase 3 studies. D3 Bio saw previous investors like WuXi AppTec's Corporate Ve... |
| 10.12.2025 | D3 Bio Secures $108 Million in Series B Financing to Advance Global Clinical Programs | SHANGHAI, Dec. 10, 2025 /PRNewswire/ -- D3 Bio, a global clinical-stage biotechnology company focused on the discovery and development of innovative oncology therapeutics, announced the completion of a $108 million Series B financing round.... |
| 28.08.2025 | D3 Bio, Inc. Announces FDA Breakthrough Therapy Designation and Orphan Drug Designation for D3S-001 for the Treatment of Patients with KRAS G12C-Mutated Cancers | Breakthrough Therapy Designation was granted for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) who have had prior treatment with platinum-based chemotherapy and anti... |
Show more